Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2002 2
2004 1
2005 3
2006 2
2007 2
2008 3
2009 6
2010 4
2011 2
2012 5
2013 4
2014 3
2015 6
2016 8
2017 7
2018 3
2019 4
2020 3
2021 4
2022 3
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections.
Yoshino I, Moriya Y, Suzuki K, Wakabayashi M, Saji H, Aokage K, Suzuki M, Ito H, Matsumoto I, Kobayashi M, Okamoto T, Okada M, Yamashita M, Ikeda N, Nakamura S, Kataoka T, Tsuboi M, Watanabe SI; West Japan Oncology Group and Japan Clinical Oncology Group. Yoshino I, et al. Among authors: yamashita m. J Thorac Cardiovasc Surg. 2023 Oct;166(4):1222-1231.e1. doi: 10.1016/j.jtcvs.2023.01.019. Epub 2023 Jan 25. J Thorac Cardiovasc Surg. 2023. PMID: 37704343 Free article.
A proposal of postoperative follow-up pathways for lung cancer.
Sawada S, Shiono S, Yamashita Y, Tagawa T, Ito H, Sato T, Harada H, Yamashita M. Sawada S, et al. Among authors: yamashita m. Gen Thorac Cardiovasc Surg. 2015 Apr;63(4):231-8. doi: 10.1007/s11748-014-0506-7. Epub 2014 Dec 18. Gen Thorac Cardiovasc Surg. 2015. PMID: 25520046 Review.
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.
Yamamoto H, Soh J, Okumura N, Suzuki H, Nakata M, Fujiwara T, Gemba K, Sano I, Fujinaga T, Kataoka M, Terazaki Y, Fujimoto N, Kataoka K, Kosaka S, Yamashita M, Inokawa H, Inoue M, Nakamura H, Yamashita Y, Hotta K, Yoshioka H, Morita S, Matsuo K, Sakamoto J, Date H, Toyooka S. Yamamoto H, et al. Among authors: yamashita m. PLoS One. 2023 May 19;18(5):e0285273. doi: 10.1371/journal.pone.0285273. eCollection 2023. PLoS One. 2023. PMID: 37205678 Free PMC article. Clinical Trial.
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery.
Fujiwara T, Shien K, Matsuura M, Soh J, Yamamoto H, Takao S, Maki Y, Ueno T, Sugimoto R, Suzawa K, Okazaki M, Tao H, Hayama M, Kataoka M, Sano Y, Inokawa H, Yamashita M, Kawamata O, Kataoka K, Toyooka S. Fujiwara T, et al. Among authors: yamashita m. Ann Surg Oncol. 2023 Oct;30(11):6697-6702. doi: 10.1245/s10434-023-13791-y. Epub 2023 Jun 25. Ann Surg Oncol. 2023. PMID: 37355521 Free PMC article.
Surgical treatments for multiple primary adenocarcinoma of the lung.
Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, Tanemoto K. Nakata M, et al. Among authors: yamashita m. Ann Thorac Surg. 2004 Oct;78(4):1194-9. doi: 10.1016/j.athoracsur.2004.03.102. Ann Thorac Surg. 2004. PMID: 15464469 Review.
Salvage Surgery for Non-Small Cell Lung Cancer After Definitive Radiotherapy.
Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M, Iizasa T, Ito H, Yoshimura K, Okada M, Chida M; Japanese Association for Chest Surgery. Shimizu K, et al. Among authors: yamashita m. Ann Thorac Surg. 2021 Sep;112(3):862-873. doi: 10.1016/j.athoracsur.2020.10.035. Epub 2020 Nov 26. Ann Thorac Surg. 2021. PMID: 33248992
73 results